A. Pursuant to a board-approved protocol approved by the New Mexico medical board, a pharmacist may order, test, screen, treat and provide preventative services for health conditions or situations that include:

(1)     influenza;

(2)     group A streptococcus pharyngitis; (3)     SARS-COV-2;

(4)     uncomplicated urinary tract infection;

(5)     human immunodeficiency virus, limited to the provision of pre-exposure prophylaxis and post-exposure prophylaxis; and

(6)     other emerging and existing public health threats identified by the board or department of health during civil or public health emergencies.

B. A pharmacist who orders, tests, screens or treats for health conditions or situations pursuant to this section may use any test that may guide clinical decision making, including tests waived pursuant to the federal Clinical Laboratory Improvement Amendments of 1988, as amended, the federal rules adopted thereunder or any established screening procedure that can safely be performed by a pharmacist.

C. A pharmacist may delegate the administrative and technical tasks of performing a test waived by the federal Clinical Laboratory Improvement Amendments of 1988, as amended, to a pharmacist intern or pharmacy technician acting under the supervision of the pharmacist.